SGLT2 Inhibition and Left Ventricular Mass
Condition(s):Diabetes Mellitus Type 2Last Updated:March 22, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Diabetes Mellitus Type 2Last Updated:March 22, 2019Terminated
Condition(s):HypertensionLast Updated:May 19, 2014Terminated
Condition(s):Newly Diagnosed Type 2 Diabetes; Coronary Artery DiseaseLast Updated:August 18, 2015Completed
Condition(s):Arterial HypertensionLast Updated:July 20, 2022Recruiting
Condition(s):Genetic Predisposition; Genetic HypertensionLast Updated:April 19, 2022Completed
Condition(s):Hypertrophy, Left VentricularLast Updated:December 16, 2016Completed
Condition(s):Left Ventriclar MassLast Updated:August 18, 2015Completed
Condition(s):Fabry DiseaseLast Updated:March 15, 2024Recruiting
Condition(s):LVM; Type 2 Diabetic Patients With IHD; Endothelial FunctionLast Updated:August 19, 2015Completed
Condition(s):Suspected Arterial HypertensionLast Updated:April 3, 2015Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.